NEW YORK, Feb. 20, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Contraceptives in US$ by the following Contraception Methods: Hormonal Contraceptives (Oral Contraceptives, & Other Hormonal Contraceptives), and Condoms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Read the full report: http://www.reportlinker.com/p04707116-summary/view-report.html
Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 92 companies including many key and niche players such as:
- Afaxys, Inc.
- Agile Therapeutics, Inc.
- Allergan plc
- Ansell Limited
- Bayer AG
Read the full report: http://www.reportlinker.com/p04707116-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Hormonal Contraceptives..............I-3 Oral Contraceptives..............I-3 Other Hormonal Contraceptives..............I-4 Condoms.............. I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 Contraceptives: Transforming Birth Control, Planned Parenthood, and Women's Health..............II-1 Table 1: Contraception Methods Relied on by Women in the 15-50 Age Group Worldwide (2016E): Percentage Share Breakdown for Female Sterilization, Implants, Injectables, IUDs, Male Condoms, Male Sterilization, Oral Pill, Withdrawal Method, and Others (Vaginal Barrier Methods) (includes corresponding Graph/Chart).............. II-3 Contraceptives Market: Fast Facts II-3 The Vital Need to Curtail the Ballooning Global Population through Birth Control: The Fundamental Growth Driver II-5 Effectiveness Index of Contraceptive Methods: Brief Details of Method, Efficacy Percentage, Benefits, Risks, and Availability.............. II-7 Unmet Contraception Needs Signals Huge Market Penetration Opportunities.............. II-9 Birth Control Methods and the Degree of Use in Major Regions Worldwide.............. II-11 Global Population Statistics: Unfurling the Market Potential II-11 Table 2: World Population by Geographic Region (2000, 2010, 2015, 2020, 2030, 2040, and 2050) (in Millions) (includes corresponding Graph/Chart)..............II-12
Table 3: World Population (2015): Population and Percentage Share Breakdown by Age Group - Below 15 Years, 15-64 Years, Above 65 Years (includes corresponding Graph/Chart) II-12 Table 4: 15-64 Year Population as a Percentage of Total Population for Major Countries: 2015 II-13 China & India: Two Countries with the Largest Sexually Active Population Offer Significant Growth Opportunities II-13 Table 5: Ten Largest Populated Countries Worldwide (July 2015): Total Population (in Millions) by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart) II-14
Table 6: Ten Largest Populated Countries Worldwide (July 2015): Percentage Population by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart)..............II-15 Global Market Outlook..............II-15
2. COMPETITION.............. II-18 Table 7: Leading Condom Companies Worldwide (2016E): Percentage Market Share of Revenues for Reckitt Benckiser, Ansell, Church & Dwight, and Others (includes corresponding Graph/Chart).............. II-18 Bayer's Oral Contraceptive Pills: In the Midst of Controversies II-19 Bayer's "Yasmin": A Resounding Brand Success Worldwide when Launched.............. II-20 Innovative Promotion Strategies Enhance Product Appeal II-20 Aging Population Adds to Manufacturer Concerns II-21 Manufacturers Capitalize on the Healthcare-Related Role of Contraceptives.............. II-21 Teen Population: A Lucrative Demographic Segment and the New Advertising Target.............. II-21 Supermarkets and Internet Gain Importance in Contraceptives Retail.............. II-22
3. MARKET TRENDS, ISSUES & DRIVERS II-23 Condoms as a Powerful Tool against HIV/AIDS and Other STIs Witness Strong Growth in Demand II-23 Condoms: Percentage Effectiveness of Protection against STDs II-24 Table 8: Number of Individuals Living with HIV Worldwide in Millions: 2000, 2005, 2010 & 2015 (includes corresponding Graph/Chart).............. II-24
Table 9: HIV Infection Statistics Worldwide (2015): Total Infected, Newly Infected, and Number of Deaths (in Millions) (includes corresponding Graph/Chart) II-25
Table 10: Global HIV Infection Statistics by Region (2015): Total Infected, Newly Infected, and Number of Deaths (in Thousands) (includes corresponding Graph/Chart) II-25 Study Reveals Positive Effects of Contraceptives on HIV- Infected Women.............. II-26 Contraceptive Innovations and Advancements: Spearheading Growth II-26 Major Condom Innovations..............II-27 "S.T.EYE": A Condom that Changes Color in the Presence of an STI.............. II-27 A Super Condom with the Potential to Eradicate HIV II-28 Other Recent Innovations in Condoms II-28 Declining Prices and Increased Accessibility of Contraceptives Benefit Market Expansion..............II-31 Despite Waning Popularity, Oral Contraceptives Continue to Sustain Market Domination..............II-32 Research Findings In Favor of and Against the Pill II-32 Considerably Lowers Death Rate from Ovarian Cancer II-32 Helps Reduce Risk of Endometrial Cancer II-33 Increases Risk of Ischemic Stroke II-33 Heightens the Risk of Crohn's Disease II-34 Oral Contraceptives - Challenges & Strategies to Overcome Problems.............. II-34 Rising Need to Develop Contraceptives for Men Drive Robust Research & Development..............II-35 Efficacy and Reduction of Side Effects: Need of the Hour for Injectable Male Contraceptives II-36 Evolving Designs and Features in Female Condoms Drive Surging Popularity and Growing Adoption II-37 Select Female Condom Brands Worldwide: A Comparison II-39 FC1 and FC2 from the Female Health Company II-40 Female Condom from PATH..............II-40 Other Major Developments in Female Condoms II-41 Convenience and Cost Benefits Drive Healthy Growth in Demand for Intrauterine Devices..............II-42 Characteristic Features of Intrauterine Devices (IUDs) II-42 Key Challenges & Strategies to Overcome Problems II-43 Increasing Standard of Living: A Key Growth Driver II-43 Table 11: Global Middle Class Population by Geographic Region: Percentage Share Breakdown for 2010, 2020P & 2030P (includes corresponding Graph/Chart) II-44 Social Stigmas in Under Developed Countries Hamper Market Prospects.............. II-44 Major Hindrances for Widespread Usages of Condoms II-44 Developing Countries Continue to Drive Current and Future Market Growth.............. II-45 Table 12: Global Contraceptives Market - Geographic Regions Ranked by CAGR (Value Sales) for 2015-2022: Asia-Pacific, Rest of World, Latin America, Europe, Canada, Japan, and USA (includes corresponding Graph/Chart) II-46 Manufacturers Depend on Emerging Markets to Increase Sales Momentum.............. II-47
4. TRADE STATISTICS.............. II-48 Table 13: Global Exports of Chemical and Hormonal Contraceptives by Country (2015): Percentage Breakdown of Value Exports for Germany, Netherlands, Belgium, Hungary, Ireland, India, France, Brazil, Canada, Switzerland, and Others (includes corresponding Graph/Chart) II-48
Table 14: Global Imports of Chemical and Hormonal Contraceptives by Country (2015): Percentage Breakdown of Value Imports for USA, Belgium, Canada, Russian Federation, Mexico, Italy, Germany, Spain, UK, Brazil, and Others (includes corresponding Graph/Chart) II-48
Table 15: Global Exports of Sheath Contraceptives by Country (2015): Percentage Breakdown of Value Exports for Thailand, Malaysia, China, India, Hong Kong, China, Japan, UK, Hungary, Germany, Singapore, and Others (includes corresponding Graph/Chart).............. II-49
Table 16: Global Imports of Sheath Contraceptives by Country (2015): Percentage Breakdown of Value Imports for China, Russian Federation, Brazil, USA, UK, Hong Kong, China, France, Italy, Germany, Singapore, and Others (includes corresponding Graph/Chart).............. II-49
5. PRODUCT OVERVIEW.............. II-50 Contraceptives: A Prelude..............II-50 Types of Contraception..............II-50 The Contraceptive Timeline..............II-50 By Function.............. II-51 Barrier Contraceptives..............II-51 Characteristic Features of Barrier Methods II-51 Hormonal Contraceptives..............II-51 Prescription Contraceptives II-51 Oral Contraceptives..............II-52 Overview of Oral Contraceptives - Benefits vs. Risks II-52 Traditional and Modern..............II-52 Reversible and Permanent..............II-53 Segmental Overview..............II-53 Hormonal Contraceptives..............II-53 Oral Contraceptives (OCs)/Pills II-53 A Peep into the Past..............II-54 Synthetic Oral Contraceptives..............II-54 Characteristic Features of Oral Contraceptives (OCs) II-54 Advantages of Using OCs..............II-55 Effects of Long-Term Use of OCs II-55 Use of OCs/Pills - Myths & Facts II-56 Factors Associated with Failure of OCs/Pills II-56 Health Conditions to be Addressed when Using OCs II-56 Understanding Risks Associated with Use of OCs II-57 Cardiovascular Disease - A Major Side Effect of OCs II-57 Intake of OCs Result in High Blood Pressure II-57 Smoking Intensifies Respiratory Problems in Pill Users II-58 Age Related Complications Associated with the Direct Use of OCs.............. II-58 Relation Between OC and Cancer II-58 Depression Linked to Use of OCs II-58 OCs Increases Osteoporosis Risk at Later Stage II-58 OCs May Reduce Sex Drive..............II-58 Effects of Pill on Childbearing Capacity II-59 Visiting a Doctor - Highly Recommended in Case of Warning Symptoms.............. II-59 Emergency Contraception (EC) - A New Face of OCs II-59 Role of ECPs.............. II-59 Effectiveness of ECP..............II-60 Different Types of EC Products II-60 Mini Pills.............. II-60 RU486 - the French Abortion Pill II-61 Availability of Hormonal Contraceptives as OTC Drugs II-61 Other Hormonal Contraceptives..............II-61 Injectable Contraceptives..............II-61 Depo-Provera.............. II-61 Characteristic Features of Injectable Contraceptives II-62 Injectables - Challenges & Strategies to Overcome Problems II-62 Intrauterine Devices (IUDs)/Implants II-63 CopperT 380A (ParaGard)..............II-63 Progesterone T (or Progestasert) II-63 Long-term Reversible Contraceptive Implants II-63 Norplant.............. II-63 Implanon.............. II-64 Mirena.............. II-64 Characteristic Features of Implantable Contraceptives II-65 Challenges & Strategies to Overcome Problems II-65 Spermicides.............. II-66 Benefits.............. II-66 Drawbacks.............. II-66 Contraceptive Foam..............II-66 Delfen Contraceptive Foam..............II-66 Contraceptive Cream or Jelly..............II-66 Encare Ovals.............. II-67 Condoms.............. II-67 Latex Condoms.............. II-67 Non-Latex Condoms.............. II-67 Skin Condoms.............. II-67 Polyurethane (PU) Condoms..............II-68 Comparison Between Polyurethane & Latex Condoms II-68 Myths & Facts.............. II-68 Selection & Effective Use of Condoms II-69 Female Condoms.............. II-69 Who are the Main Users?..............II-69 Important Regulations Governing Condom Exports II-70 Regulatory Procedures in Select Countries II-70
6. PRODUCT LAUNCHES & APPROVALS..............II-71 Allergan Launches Combination Oral Contraceptive Capsule Taytulla II-71 Teva Pharmaceutical Launches Generic Oral Contraceptive RAJANITM II-71 Amneal Pharmaceuticals Launches Generic Contraceptive Femynor II-71 Tata Motors Launches Dipper Condom Brand II-71 Agile Therapeutics Announces Advancement of Contraceptive Pipeline.............. II-71 Glenmark Pharmaceuticals Receives USFDA Tentative Approval for Lo Loestrin Fe Generic..............II-71 Karex Acquires TheyFit LLC, Rebrands Custom-Fit Condoms under ONE Brand.............. II-71 WomanCare Global Launches Female Condom in Zambia II-72 DKT international Launches Fiesta Condoms in Tanzania II-72 Lupin Receives FDA Approval to Market Generic Version of Warner Chilcott's Generess Fe II-72 Lupin Launches Generic Oral Contraceptive II-72 Aurobindo Pharma Receives Approval to Market OC Levonorgestrel II-72 PSI Malawi Launches Non-Latex 'Whisper' Female Condom II-72 Pfizer Launches Sayana®Press in UK II-72 Mylan Receives Approval to Market Generic Version of Bayer's OC Yasmin.............. II-73 Teva Europe Launches Extended-Regimen OC Seasonique II-73 Convex Corporation Launches 'Convex' Brand of Male Condoms II-73 Teva Pharmaceuticals Announces Generic for Lomedia® 24 Fe II-73 ONE® Condoms Launches VANISH™ Hyperthin® Condoms II-73 Mylan N.V. Launches Generic Version of Seasonale Tablets II-73 Bayer Indonesia Launches OC Based on Estradiol with Additional Benefits.............. II-73 Afaxys Pharmaceuticals Launches EContra™ EZ Emergency Contraceptive.............. II-73 Glenmark Generics Launches Ashlyna™ Extended-Cycle Oral Contraceptive.............. II-74 Afaxys Pharmaceuticals Launches Tarina™ Oral Contraceptive II-74 Mylan Launches Generic Version of Warner Chilcott's Loestrin 24 Fe®.............. II-74 Lupin Pharmaceuticals Launches Nikki Oral Contraceptive Tablets II-74 Starpharma Receives Australian Therapeutic Goods Administration Approval for VivaGel® Condom II-74 MicroCHIPS Develops Remote Operable Contraceptive Implant II-74 Teva Pharmaceutical Receives CHMP Positive Opinion for Seasonique®.............. II-75 Lupin Pharmaceuticals Launches Vyfemla™ Oral Contraceptive II-75 Mylan Pharmaceutical Launches Generic Contraceptive Transdermal Patch Xulane..............II-75 Consilient Health Launches Lucette® Oral Contraceptive II-75
7. RECENT INDUSTRY ACTIVITY..............II-76 Female Health Company Receives Tender Award from Brazilian Municipality.............. II-76 Starpharma Holdings Signs License Agreement with Koushan Pharmed II-76 Female Health Company Completes Merger with Aspen Park Pharmaceuticals.............. II-76 Teva Pharmaceuticals to sell Rights to 79 Pharmaceuticals II-76 Starpharma Holdings Signs License Agreement with Shenyang Sky and Land.............. II-76 Karex Berhad Acquires UK-Based Pasante Healthcare II-76 Mayne Pharma Group to Acquire Generic Drug Portfolio from Teva Pharmaceuticals.............. II-76 Bayer Partners with USAID for Better Local Accessibility of OC Microgynon Fe.............. II-77 Reckitt Benckiser Signs Agreement to Acquire Hypermarcas' Condom Business.............. II-77 Karex Bhd's Subsidiary Signs Agreement to Buy US Condom Maker TheyFit LLC.............. II-77 Bayer to Offer its Contraceptive Implant Jadelle at Half-Price in Poor Countries..............II-77 Karex Expands Condoms Production Capacity II-77 Mylan Laboratories Limited Acquires Women's Healthcare Business from Famy Care..............II-77 Merck Extends Access Pricing for Contraceptive Implants II-77 Karex Acquires Medical-Latex (Dua) Sdn Bhd from Beiersdorf AG II-77 Female Health Company Receives Tender Award through its Distributor Barrs Medical..............II-78 Bayer HealthCare Enters into Alliance with Afaxys Regarding IUD Marketing.............. II-78 Afaxys Pharmaceuticals Enters into Partnership with Project Ruby II-78 Mithra Pharmaceuticals Acquires Women's Health Portfolio from Uteron Pharma.............. II-78 Gedeon Richter Enters into License and Distribution Agreement with Bayer for Contraceptive Patch II-78 Pfizer Enters into Agreement to Expand Access to Sayana® Press in Poor Countries..............II-78 Cupid Signs 10-year Condom Supply Agreement with Safeware & Co. II-78 Reckitt Benckiser Group Acquires K-Y Brand from McNEIL-PPC II-79 TTK Protective Devices Ltd to Merge with TTK Healthcare II-79
8. FOCUS ON SELECT GLOBAL PLAYERS..............II-80 Afaxys, Inc. (USA)..............II-80 Agile Therapeutics, Inc. (USA) II-80 Allergan plc (Ireland)..............II-80 Ansell Limited (Australia)..............II-81 Bayer AG (Germany)..............II-81 Church & Dwight Co., Inc. (USA)..............II-81 Fuji Latex Co. Ltd. (Japan)..............II-82 Janssen Pharmaceuticals, Inc. (USA) II-82 Karex Berhad (Malaysia)..............II-83 Lupin Pharmaceuticals Inc. (USA) II-83 Mankind Pharma Ltd. (India)..............II-83 Merck Sharp & Dohme Corp. (UK) II-84 Mayer Laboratories, Inc. (USA) II-84 Okamoto Industries, Inc. (Japan) II-84 Pfizer, Inc. (USA)..............II-85 Piramal Enterprises Ltd. (India) II-85 Reckitt Benckiser Group Plc. (UK) II-86 Sagami Rubber Industries Co., Ltd. (Japan) II-86 Teva Pharmaceutical Industries Ltd. (Israel) II-86 Thai Nippon Rubber Industry Co., Ltd. (Thailand) II-87 The Female Health Company/Veru Healthcare (USA) II-87
9. GLOBAL MARKET PERSPECTIVE..............II-88 Table 17: World Recent Past, Current and Future Analysis for Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-88
Table 18: World Historic Review for Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-89
Table 19: World 14-Year Perspective for Contraceptives by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-90 By Contraception Method:..............II-91 Table 20: World Recent Past, Current and Future Analysis for Hormonal Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-91
Table 21: World Historic Review for Hormonal Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-92
Table 22: World 14-Year Perspective for Hormonal Contraceptives by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-93
Table 23: World Recent Past, Current and Future Analysis for Hormonal Contraceptives by Type - Oral Contraceptives and Other Hormonal Contraceptives Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-94
Table 24: World Historic Review for Hormonal Contraceptives by Type - Oral Contraceptives and Other Hormonal Contraceptives Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-95
Table 25: World 14-Year Perspective for Hormonal Contraceptives by Type - Percentage Breakdown of Dollar Sales for Oral Contraceptives and Other Hormonal Contraceptives Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. II-96
Table 26: World Recent Past, Current and Future Analysis for Oral Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-97
Table 27: World Historic Review for Oral Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-98
Table 28: World 14-Year Perspective for Oral Contraceptives by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-99
Table 29: World Recent Past, Current and Future Analysis for Other Hormonal Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-100
Table 30: World Historic Review for Other Hormonal Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-101
Table 31: World 14-Year Perspective for Other Hormonal Contraceptives by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-102
Table 32: World Recent Past, Current and Future Analysis for Condoms by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-103
Table 33: World Historic Review for Condoms by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-104
Table 34: World 14-Year Perspective for Condoms by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. II-105
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Better Options and Newer Technologies in Contraception Drive Steady Market Growth..............III-1 Quick Facts on Contraception..............III-1 Relentless Promotional Programs Drive Market Adoption III-2 Potential Revoking of Affordable Care Act Lead to Surge in Demand for LARC..............III-2 Clinic Budgets Adversely Impacted by Heightened LARC Demand III-3 Inefficiency of Existing Contraception Methods Offer Immense Opportunities for Intrauterine Devices (IUDs) III-3 Measures to Overcome Lack of Awareness III-4 Downfall of the Earlier Versions III-4 Cost Factor.............. III-5 IUDs: Preferred Contraceptive among Doctors III-5 FDA Issues New Guidance and Black Box Warning for Contraceptive Implants..............III-6 Development of Effective and Safe Male Contraceptives: The Saga Continues ............... III-6 Innovative and Advanced Female Contraceptives Boost Market Prospects.............. III-7 New Single-Size Diaphragm..............III-8 Surging Popularity of Custom-Fit and Pleasure-Oriented Condoms Drive Faster Growth in Condom Sales III-9 HIV/AIDS Incidence in the US: An Important Opportunity Indicator for Condoms..............III-9 Table 35: Percentage of HIV/AIDS Cases in the US, by Gender: 1993-2029 (includes corresponding Graph/Chart) III-10 Competitive Landscape..............III-10 Domestic Players Face Tough Competition from Foreign Brands III-10 Condoms Market Highly Concentrated in the US III-11 Table 36: Leading Condom Companies in the US (2015): Market Share Breakdown of Sales for Church and Dwight, Ansell America, Reckitt Benckiser, and Others (includes corresponding Graph/Chart) III-11
Table 37: Condom Sales in the US Drug Stores by Leading Players (2015): Market Share Breakdown for Church and Dwight, Ansell America, Reckitt Benckiser, and Others (includes corresponding Graph/Chart) III-12
Table 38: Leading Condom Brands in the US (2016): Percentage Share Breakdown for Durex, Trojan & Others (includes corresponding Graph/Chart) III-12 Trade Statistics..............III-12 Table 39: US Exports of Hormonal/Spermicidal Contraceptives by Destination Country (2015): Percentage Breakdown of Value Exports (includes corresponding Graph/Chart) III-12
Table 40: US Imports of Hormonal/Spermicidal Contraceptives by Country of Origin (2015): Percentage Breakdown of Value Imports (includes corresponding Graph/Chart) III-13
Table 41: US Exports of Sheath Contraceptives by Destination Country (2015): Percentage Breakdown of Value Exports (includes corresponding Graph/Chart) III-13
Table 42: US Imports of Sheath Contraceptives by Country of Origin (2015): Percentage Breakdown of Value Imports (includes corresponding Graph/Chart) III-13 Product Launches..............III-14 Strategic Corporate Developments III-17 Select Key Players..............III-18 B.Market Analytics..............III-22 Table 43: US Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-22
Table 44: US Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-23
Table 45: US 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-24
2. CANADA.............. III-25 A.Market Analysis.............. III-25 Trade Statistics..............III-25 Table 46: Canadian Exports of Hormonal/ Spermicidal Contraceptives by Destination Country (2015): Percentage Breakdown of Value Exports (includes corresponding Graph/Chart).............. III-25
Table 47: Canadian Imports of Hormonal/ Spermicidal Contraceptives by Country of Origin (2015): Percentage Breakdown of Value Imports (includes corresponding Graph/Chart).............. III-25
Table 48: Canadian Exports of Sheath Contraceptives by Destination Country (2015): Percentage Breakdown of Value Exports (includes corresponding Graph/Chart) III-26
Table 49: Canadian Imports of Sheath Contraceptives by Country of Origin (2015): Percentage Breakdown of Value Imports (includes corresponding Graph/Chart) III-26 B.Market Analytics..............III-27 Table 50: Canadian Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-27
Table 51: Canadian Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-28
Table 52: Canadian 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-29
3. JAPAN.............. III-30 A.Market Analysis.............. III-30 Growing Overseas Demand Offer Major Boost to Japanese Condoms III-30 Local Manufacturers Expand Capacity to Meet Growing Demand III-30 Major Condom Brands in Japan III-31 Crown and Beyond Seven..............III-31 Kimono Condoms.............. III-31 Impact of Legalization of Oral Contraceptives III-31 Select Key Players..............III-32 B.Market Analytics..............III-33 Table 53: Japanese Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-33
Table 54: Japanese Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-34
Table 55: Japanese 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-35
4. EUROPE.............. III-36 Market Analysis.............. III-36 Table 56: European Recent Past, Current & Future Analysis for Contraceptives by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-37
Table 57: European Historic Review for Contraceptives by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-38
Table 58: European 14-Year Perspective for Contraceptives by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-39
Table 59: European Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-40
Table 60: European Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-41
Table 61: European 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-42
4a. FRANCE.............. III-43 Market Analysis.............. III-43 Table 62: French Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-43
Table 63: French Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-44
Table 64: French 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-45
4b. GERMANY.............. III-46 A.Market Analysis.............. III-46 Strategic Corporate Development III-46 Bayer AG: A Major Germany-based Company III-46 B.Market Analytics..............III-47 Table 65: German Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-47
Table 66: German Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-48
Table 67: German 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-49
4c. ITALY.............. III-50 A.Market Analysis.............. III-50 Product Launch.............. III-50 B.Market Analytics..............III-51 Table 68: Italian Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-51
Table 69: Italian Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-52
Table 70: Italian 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-53
4d. THE UNITED KINGDOM..............III-54 A.Market Analysis.............. III-54 Contraceptives: A Mature Market III-54 Table 71: Condom Usage in the UK (2015): Breakdown of Usage Rate by Gender and Age (includes corresponding Graph/Chart) III-54 Durex: The Dominant Condom Brand in the UK III-55 Product Launches..............III-55 Strategic Corporate Developments III-55 Select Key Players..............III-56 B.Market Analytics..............III-57 Table 72: The UK Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-57
Table 73: The UK Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-58
Table 74: The UK 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-59
4e. SPAIN.............. III-60 Market Analysis.............. III-60 Table 75: Spanish Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-60
Table 76: Spanish Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-61
Table 77: Spanish 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-62
4f. RUSSIA.............. III-63 A.Market Analysis.............. III-63 Lower Prices in Comparison to Oral Contraceptives Drive Faster Growth in Demand for Condoms III-63 B.Market Analytics..............III-64 Table 78: Russian Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-64
Table 79: Russian Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-65
Table 80: Russian 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-66
4g. REST OF EUROPE.............. III-67 A.Market Analysis.............. III-67 Strategic Corporate Developments III-67 Allergan plc - A Major Ireland-Based Company III-67 B.Market Analytics..............III-68 Table 81: Rest of European Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-68
Table 82: Rest of European Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-69
Table 83: Rest of European 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-70
5. ASIA-PACIFIC.............. III-71 A.Market Analysis.............. III-71 Large Populations in Asian Countries Turbo Charge Global Market Growth.............. III-71 China & India: Two Countries with the Largest Young Population Offer Significant Growth Opportunities III-71 Table 84: Ten Largest Populated Countries Worldwide (July 2015): Total Population (in Millions) by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart) III-72
Table 85: Ten Largest Populated Countries Worldwide (July 2015): Percentage Population by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart)..............III-73 Rising HIV/AIDS Prevalence Drive Strong Demand for Condoms III-74 Table 86: HIV/AIDS Stats in Asia (2014) (includes corresponding Graph/Chart)..............III-74
Table 87: Top Twelve Countries in Asia-Pacific with the Highest HIV Incidence (2012) (includes corresponding Graph/Chart).............. III-75 B.Market Analytics..............III-76 Table 88: Asia-Pacific Recent Past, Current & Future Analysis for Contraceptives by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-76
Table 89: Asia-Pacific Historic Review for Contraceptives by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-77
Table 90: Asia-Pacific 14-Year Perspective for Contraceptives by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-78
Table 91: Asia-Pacific Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-79
Table 92: Asia-Pacific Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-80
Table 93: Asia-Pacific 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-81
5a. CHINA.............. III-82 A.Market Analysis.............. III-82 End of One-Child Policy: Only a Temporary Setback III-82 Table 94: Total Population (Millions) in China: 1950, 2015, and 2030 (includes corresponding Graph/Chart) III-83 Key Trends in the Chinese Condoms Market III-83 Imported Condoms: A Big Hit in China III-83 Fight against HIV to Augur Well for Condoms Market III-83 Chinese Condom Makers Eyeing Smaller Cities to Spruce up Sales III-84 Counterfeit Products: A Bane for the Chinese Condoms Market III-84 Trade Statistics..............III-85 Table 95: Chinese Import and Export Data of Hormonal Contraceptives (2016, 2015 & 2014): Import/Export Volume (Kg) and Import/Export Value (US$ Million) (includes corresponding Graph/Chart)..............III-85
Table 96: Chinese Import and Export Data of Sheath Contraceptives (2016, 2015 & 2014): Import/Export Volume (Kg) and Import /Export Value (US$ Million) (includes corresponding Graph/Chart)..............III-86 Strategic Corporate Development III-86 B.Market Analytics..............III-87 Table 97: Chinese Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-87
Table 98: Chinese Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-88
Table 99: Chinese 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-89
5b. INDIA.............. III-90 A.Market Analysis.............. III-90 The Urgent Need for Population Control Drives Market Demand III-90 Table 100: Total Population (Millions) in India: 1950, 2015, and 2030 (includes corresponding Graph/Chart) III-90 Innovative Media Campaigns Boost Condom Sales III-91 Social Stigma Continues to Hamper Market Growth, Despite Improvements in Retailing..............III-91 Indiscreet Usage of Emergency Contraceptive (EC) on the Rise III-92 Table 101: Leading Condom Brands in India (2016): Percentage Share Breakdown for Durex, Kama Sutra, Manforce, Moods & Skore (includes corresponding Graph/Chart) III-92 Product Launches..............III-93 Strategic Corporate Developments III-93 Select Key Players..............III-93 B.Market Analytics..............III-96 Table 102: Indian Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-96
Table 103: Indian Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-97
Table 104: Indian 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-98
5c. REST OF ASIA-PACIFIC..............III-99 A.Market Analysis.............. III-99 Thailand Emerge as a Leading Global Condoms Exporter III-99 Product Launches..............III-100 Strategic Corporate Developments III-100 Select Key Players..............III-101 B.Market Analytics..............III-103 Table 105: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-103
Table 106: Rest of Asia-Pacific Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-104
Table 107: Rest of Asia-Pacific 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-105
6. LATIN AMERICA.............. III-106 A.Market Analysis.............. III-106 Strategic Corporate Development III-106 B.Market Analytics..............III-107 Table 108: Latin American Recent Past, Current & Future Analysis for Contraceptives by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-107
Table 109: Latin American Historic Review for Contraceptives by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-108
Table 110: Latin American 14-Year Perspective for Contraceptives by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin America Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-109
Table 111: Latin American Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-110
Table 112: Latin American Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-111
Table 113: Latin American 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-112
6a. BRAZIL.............. III-113 A.Market Analysis.............. III-113 High National Regulation Standards III-113 B.Market Analytics..............III-114 Table 114: Brazilian Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-114
Table 115: Brazilian Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-115
Table 116: Brazilian 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-116
6b. REST OF LATIN AMERICA..............III-117 Market Analysis.............. III-117 Table 117: Rest of Latin American Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-117
Table 118: Rest of Latin American Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-118
Table 119: Rest of Latin American 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-119
7. REST OF WORLD.............. III-120 A.Market Analysis.............. III-120 Underdeveloped African Markets Present Huge Market Potential III-120 South Africa: Government Programs Drive Popularity of Female Condoms.............. III-121 Product Launches..............III-121 Strategic Corporate Developments III-122 Teva Pharmaceutical Industries Limited: A Major Israel-Based Company.............. III-123 B.Market Analytics..............III-124 Table 120: Rest of World Recent Past, Current & Future Analysis for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-124
Table 121: Rest of World Historic Review for Contraceptives by Contraception Method - Hormonal Contraceptives (Oral and Others) and Condoms Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-125
Table 122: Rest of World 14-Year Perspective for Contraceptives by Contraception Method - Percentage Breakdown of Dollar Sales for Hormonal Contraceptives (Oral and Others) and Condoms Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-126
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 92 (including Divisions/Subsidiaries - 104)
The United States (25) Canada (1) Japan (3) Europe (24) - France (3) - Germany (6) - The United Kingdom (5) - Italy (1) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (43) Latin America (6) Africa (2)
Read the full report: http://www.reportlinker.com/p04707116-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article